4th Annual Cell Engager Therapeutics Summit 2022 | May 24-26 2022 | Boston, MA

Kongressthemen
With TCEs being studied in both hematological and solid tumors (39 and 34 trials respectively), there are now more than one hundred projects in the preclinical stage.
Early clinical outcomes and novel TCE design modifications have fueled the development and clinical advancement of over 65 bispecific T-cell engagers (TCEs), which are presently in Phase I and Phase II investigations since the Cell Engager Series began.

Kongressorganizer (PCO)
Hanson Wade

Anmerkungen
Speakers: Antara Banerjee Associate Director, Immunology Research and Group Leader, Immuno Biologics Takeda Pharmaceutical Co. Ltd., Julie Bailis Director of Research Amgen Inc and more.

https://go.evvnt.com/1011482-1?pid=4832

Frau Rosie Andre